0.99 USD
▲+0.04+4.57%
盘后 0.97 -2.43%
2026-11-20
市值
$13.20M
市盈率
—
EPS
-2.61
股息率
—
52 周区间
0.77 – 5.69
成交量
161.56K
Beta
—
目标价
8.75
52W 低 0.7752W 高 5.69
价格走势
公司简介
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI...